Neohepatect (Human Hepatitis B Immunoglobulin)

The immunoglobulin contains high‑titer anti‑HBs antibodies that bind to hepatitis B surface antigen, neutralizing the virus and blocking its entry into liver cells. This rapid increase in circulating antibodies offers immediate protection while the patient’s own immune system develops a longer‑term response.

The dosage of Neohepatect is determined by the prescribing clinician based on the patient’s weight, exposure risk, and clinical context. The prescriber sets the exact amount and infusion rate according to established guidelines and individual patient needs.

Safety data for Neohepatect in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Neohepatect, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and import documentation.

Neohepatect provides passive immunity through high‑titer anti‑HBs antibodies, offering immediate protection, whereas hepatitis B vaccines stimulate active immunity over weeks. Compared with other HBIG products, Neohepatect is sourced from EU‑approved plasma and meets GMP standards, delivering comparable efficacy and safety profiles.

Neohepatect must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration.

Neohepatect is given as an intravenous infusion by a qualified healthcare professional. The infusion rate and volume are set according to the prescribed dose, and the patient should be monitored for any immediate adverse reactions during and after the administration.

The most serious risks include severe allergic reactions such as anaphylaxis, serum sickness‑like reactions, and rare cases of renal dysfunction. Prompt medical attention is required if symptoms such as difficulty breathing, rash, fever, or reduced urine output occur.

Neohepatect should not be used in individuals with a known hypersensitivity to human immunoglobulin preparations or any of its excipients. Caution is advised in patients with severe renal impairment, and it is contraindicated in those with a history of severe anaphylactic reactions to immunoglobulins.